Sirius Therapeutics Co., Ltd.

This early-stage study tests a new medicine called SRSD216, given as a shot under the skin, in people with high levels of lipoprotein(a) — a genetic risk factor for heart disease. The goal is to see if the drug is safe and how it affects Lp(a) levels in the blood. About 84 adults…

This study tests a new drug called SRSD107 to see if it works better than the standard blood thinner enoxaparin at preventing dangerous blood clots after knee replacement surgery. About 450 adults aged 60 to 80 will receive either SRSD107 or enoxaparin before and after surgery. T…

This study tests a new drug called SRSD107 in people with long-term heart or artery disease. The goal is to see if it safely lowers a protein linked to blood clots, which could reduce the risk of heart attacks or strokes. About 104 adults will receive either the drug or a placebo…